XPH Looks Tempting, but the Five-Year Chart Warns Investors
SPDR S&P Pharmaceuticals ETF has delivered a standout one-year run, yet the longer five-year view casts a shadow. The...
Understand the reasons for choosing a retirement plan over a 401k. Make informed decisions for a secure retirement.
23,531 articlesSPDR S&P Pharmaceuticals ETF has delivered a standout one-year run, yet the longer five-year view casts a shadow. The...
IBM argues that data gravity keeps information in place. This investing piece explains why that matters, how AI reinf...
Alta Fox quietly increases its XPEL exposure, lifting the stake to about 15.5% after a roughly $58 million purchase. ...
Palantir stock soared today as investors priced in a mix of solid results, new government and enterprise wins, and a ...
Four dividend stocks flying under the radar are stepping into the spotlight as they lift dividends and beat Q4 estima...
Ford and GM are reshaping their business models by moving into energy-related assets like batteries, charging network...
Leveraged ETFs promise fast gains, but they can also magnify losses. This guide explains how they work, when they mig...
As AI-driven growth cools, value stocks may take the lead. This guide shows how to spot undervalued names, avoid trap...
A focused $8 million investment could trigger a dramatic move in a biotech stock. Learn how three NDA filings and a d...
Insider stock moves can spark questions about a company's future. This guide breaks down what viasat's chief accounti...
Spring usually fuels home buying, but this year the market gets rocky as the Fed delays rate cuts. Learn what it mean...
A contrarian approach that looks beyond flashy tech names. Learn how to find a dirt cheap growth stock with solid fun...